Trial · NCT06964165
Results by group2,616
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 2,616
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | Platinum-taxane | 70.6 | 95% Confidence Interval 44.04 to 89.69 | Percentage of Participants | |
| Pre-Interval Debulking Surgery (IDS) Unconfirmed Overall Response Rate (ORR) | Niraparib | 31.6 | 95% Confidence Interval 16.34 to 67.71 | Percentage of Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Platinum-taxane | Criteria 1 | 0 | Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Niraparib | Criteria 1 | 0 | Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Platinum-taxane | Criteria 2 | 0 | Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Niraparib | Criteria 2 | 0 | Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Platinum-taxane | Criteria 3 | 0 | Participants | |
| Number of Participants With Cancer Antigen (CA)-125 Progression by Gynecological Cancer InterGroup (GCIG) CA-125 Response Criteria | Niraparib | Criteria 3 | 0 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Baseline, Severity, 0=None | 10 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Baseline, Severity, 0=None | 9 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Baseline, Severity, 1=Mild | 3 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Baseline, Severity, 1=Mild | 4 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate | 1 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Baseline, Severity, 2=Moderate | 3 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Baseline, Severity, 3=Severe | 0 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Baseline, Severity, 3=Severe | 1 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe | 0 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Baseline, Severity, 4=Very severe | 0 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Platinum-taxane | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None | 6 | Participants | |
| Number of Participants With Frequency and Severity of Items as Measured by Patient Reported Outcomes of the Common Terminology Criteria for Adverse Events (PRO-CTCAE) | Niraparib | Probs Tasting Food/Drink, Cycle 1 Day 8, Severity, 0=None | 7 | Participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06964165/results